Cross-modulation and molecular interaction at the cav3.3 protein between the endogenous lipids and the T-Type calcium channel Antagonist TTA-A2.

Molecular Pharmacology

Volumn 85, Issue 2, 2014, Pages 218-225

  Cazade, Magali ^a   Nuss, Cindy E ^b   Bidaud, Isabelle ^a   Renger, John J ^b   Uebele, Victor N ^b   Lory, Philippe ^c   Chemin, Jean ^a  

^a INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^b INSERM   (France)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 CYCLOPROPYLPHENYL) N [1 [5 (2,2,2 TRIFLUOROETHOXY)PYRIDIN 2 YL]ACETAMIDE]; [2 [4 (TERTBUTYL)PHENYL] N [1 (5 METHOXYPYRIDIN 2 YL)ETHYL]ACETAMIDE] H 3; [4 [6 CHLORO 4 CYCLOPROPYL 3 (2,2 DIFLUOROETHYL) 2 OXO 1,2,3,4 TETRAHYDROQUINAZOLIN 4 YL]BENZONITRILE]; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; LIPID; N ACYLAMINO ACID; N ARACHIDONOYL DOPAMINE; N ARACHIDONOYL GLYCINE; N ARACHIDONOYL SERINE; N ARACHIDONOYL SEROTONIN; N ARACHIDONOYL TAURINE; N ARACHIDOYL ETHANOLAMINE; N ARACHIDOYL GLYCINE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BINDING ASSAY; BRAIN ELECTROPHYSIOLOGY; CALCIUM CURRENT; CELL STRAIN HEK293; CONTROLLED STUDY; CROSS MODULATION; DRUG BINDING; EMBRYO; HUMAN; HUMAN CELL; MEMBRANE BINDING; MODULATION; MOLECULAR INTERACTION; PRIORITY JOURNAL; RADIOACTIVITY;

EID: 84891881348     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.089581     Document Type: Article

References (46)

1. Barbara G, Alloui A, Nargeot J, Lory P, Eschalier A, Bourinet E, and Chemin J (2009) T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. J Neurosci 29:13106-13114
2. Basbaum AI, Bautista DM, Scherrer G, and Julius D (2009) Cellular and molecular mechanisms of pain. Cell 139:267-284
3. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, and Mechoulam R (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353:23-31
4. Bisogno T, Melck D, Bobrov MYu, Gretskaya NM, Bezuglov VV, De Petrocellis L, and Di Marzo V (2000) N-acyl-dopamines: novel synthetic CB(1) cannabinoidreceptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351:817-824
5. Bisogno T, Melck D, De Petrocellis L, Bobrov MYu, Gretskaya NM, Bezuglov VV, Sitachitta N, Gerwick WH, and Di Marzo V (1998) Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 248:515-522
6. Bradshaw HB and Walker JM (2005) The expanding field of cannabimimetic and related lipid mediators. Br J Pharmacol 144:459-465
7. Burstein S (2008) The elmiric acids: biologically active anandamide analogs. Neuropharmacology 55:1259-1264
8. Cain SM and Snutch TP (2010) Contributions of T-type calcium channel isoforms to neuronal firing. Channels (Austin) 4:475-482
9. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, and Lory P (2001) Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J 20:7033-7040
10. Chemin J, Nargeot J, and Lory P (2007) Chemical determinants involved in anandamide-induced inhibition of T-type calcium channels. J Biol Chem 282: 2314-2323
11. Chen C and Bazan NG (2005) Lipid signaling: sleep, synaptic plasticity, and neuroprotection. Prostaglandins Other Lipid Mediat 77:65-76
12. Childers SR, Sexton T, and Roy MB (1994) Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmacol 47:711-715
13. Danthi SJ, Enyeart JA, and Enyeart JJ (2005) Modulation of native T-type calcium channels by omega-3 fatty acids. Biochem Biophys Res Commun 327:485-493
14. De Petrocellis L, Davis JB, and Di Marzo V (2001) Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 506: 253-256
15. Deutsch DG and Chin SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46:791-796
16. Francois A, Kerckhove N, Meleine M, Alloui A, Barrere C, Gelot A, Uebele VN, Renger JJ, Eschalier A, and Ardid D et al. (2013) State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects. Pain 154:283-293
17. Gilmore AJ, Heblinski M, Reynolds A, Kassiou M, and Connor M (2012) Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HT. Br J Pharmacol 167:1076-1088
18. Giordanetto F, Knerr L, and Wallberg A (2011) T-type calcium channels inhibitors: a patent review. Expert Opin Ther Pat 21:85-101
19. Ho WS, Barrett DA, and RandallMD (2008) 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 155:837-846
20. Huang SM, Bisogno T, Petros TJ, Chang SY, Zavitsanos PA, Zipkin RE, Sivakumar R, Coop A, Maeda DY, and De Petrocellis L et al. (2001) Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem 276:42639-42644
21. Kraus RL, Li Y, Gregan Y, Gotter AL, Uebele VN, Fox SV, Doran SM, Barrow JC, Yang ZQ, and Reger TS et al. (2010) In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J Pharmacol Exp Ther 335:409-417
22. Kuo IY, Wölfle SE, and Hill CE (2011) T-type calcium channels and vascular function: the new kid on the block? J Physiol 589:783-795
23. Leaf A, Xiao YF, Kang JX, and Billman GE (2003) Prevention of sudden cardiac death by n-3 polyunsaturated fatty acids. Pharmacol Ther 98:355-377
24. Lee J and Shin HS (2007) T-type calcium channels and thalamocortical rhythms in sleep: a perspective from studies of T-type calcium channel knockout mice. CNS Neurol Disord Drug Targets 6:63-69
25. Lory P, Bidaud I, and Chemin J (2006) T-type calcium channels in differentiation and proliferation. Cell Calcium 40:135-146
26. Lory P and Chemin J (2007) Towards the discovery of novel T-type calcium channel blockers. Expert Opin Ther Targets 11:717-722
27. Martin RL, Lee JH, Cribbs LL, Perez-Reyes E, and Hanck DA (2000) Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther 295:302-308
28. McGivern JG (2006) Pharmacology and drug discovery for T-type calcium channels. CNS Neurol Disord Drug Targets 5:587-603
29. Ono K and Iijima T (2010) Cardiac T-type Ca(21) channels in the heart. J Mol Cell Cardiol 48:65-70
30. Perez-Reyes E (2003) Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 83:117-161
31. Pinto JC, Potié F, Rice KC, Boring D, Johnson MR, Evans DM, Wilken GH, Cantrell CH, and Howlett AC (1994) Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol Pharmacol 46:516-522
32. Reger TS, Yang ZQ, Schlegel KA, Shu Y, Mattern C, Cube R, Rittle KE, McGaughey GB, Hartman GD, and Tang C et al. (2011) Pyridyl amides as potent inhibitors of T-type calcium channels. Bioorg Med Chem Lett 21:1692-1696
33. Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185
34. Ross HR, Gilmore AJ, and Connor M (2009) Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. Br J Pharmacol 156:740-750
35. Saghatelian A, McKinney MK, Bandell M, Patapoutian A, and Cravatt BF (2006) A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry 45:9007-9015
36. Saghatelian A, Trauger SA, Want EJ, Hawkins EG, Siuzdak G, and Cravatt BF (2004) Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry 43:14332-14339
37. Santi CM, Cayabyab FS, Sutton KG, McRory JE, Mezeyova J, Hamming KS, Parker D, Stea A, and Snutch TP (2002) Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci 22:396-403
38. Talavera K, Staes M, Janssens A, Droogmans G, and Nilius B (2004) Mechanism of arachidonic acid modulation of the T-type Ca21 channel alpha1G. J Gen Physiol 124:225-238
39. Todorovic SM and Jevtovic-Todorovic V (2013) Neuropathic pain: role for presynaptic T-type channels in nociceptive signaling. Pflugers Arch 465:921-927
40. Uebele VN, Gotter AL, Nuss CE, Kraus RL, Doran SM, Garson SL, Reiss DR, Li Y, Barrow JC, and Reger TS et al. (2009a) Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice. J Clin Invest 119:1659-1667
41. Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, Kraus RL, Santarelli VP, Li Y, and Barrow JC et al. (2009b) Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys 55:81-93
42. Uslaner JM, Smith SM, Huszar SL, Pachmerhiwala R, Hinchliffe RM, Vardigan JD, Nguyen SJ, Surles NO, Yao L, and Barrow JC et al. (2012) T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats. Neuropharmacology 62: 1413-1421
43. Uslaner JM, Vardigan JD, Drott JM, Uebele VN, Renger JJ, Lee A, Li Z, Le AD, and Hutson PH (2010) T-type calcium channel antagonism decreases motivation for nicotine and blocks nicotine- and cue-induced reinstatement for a response previously reinforced with nicotine. Biol Psychiatry 68:712-718
44. Weiss N and Zamponi GW (2013) Control of low-threshold exocytosis by T-type calcium channels. Biochim Biophys Acta 1828:1579-1586
45. Xie X, Van Deusen AL, Vitko I, Babu DA, Davies LA, Huynh N, Cheng H, Yang N, Barrett PQ, and Perez-Reyes E (2007) Validation of high throughput screening assays against three subtypes of Ca(v)3 T-type channels using molecular and pharmacologic approaches. Assay Drug Dev Technol 5:191-203
46. Zhang Y, Cribbs LL, and Satin J (2000) Arachidonic acid modulation of alpha1H, a cloned human T-type calcium channel. Am J Physiol Heart Circ Physiol 278:H184-H193.